COVID-19

NON-INVASIVE MICROCIRCULATORY DEVICE COULD HELP COVID-19 PATIENTS WITH UNDERLYING MEDICAL CONDITIONS

We are currently conducting clinical trials, and accepting product donation requests from nurses and doctors to provide D’OXYVA® for immediate lifesaving treatment of hospital patients in critical condition due to our Investigational Device Exemption (IDE) status under FDA regulations.

If this is an emergency and you need immediate assistance please email us at info@doxyva.com. 

Are You A …
HEALTHCARE PROFESSIONAL
NON - HEALTHCARE PROFESSIONAL
DID YOU KNOW?
Older age, showing signs of sepsis on admission, underlying diseases like high blood pressure and diabetes, and the prolonged use of non-invasive ventilation were important factors in the deaths of these patients, said study author Dr. Zhibo Liu.
DID YOU KNOW?
Blood pressure was the most common underlying condition, making up 30% of the co-morbidities, followed by diabetes at 19%.
DID YOU KNOW?
Death was linked to a higher score on the Sequential Organ Failure Assessment – a measure of sepsis – upon hospital arrival. Overall, all the deceased (100%) had sepsis, versus less than half (42%) of the survivors.
DID YOU KNOW?
Nearly all (98%) of the fatalities developed respiratory failure compared to 36% of the survivors. This occurs when insufficient levels of oxygen pass from the lungs to the blood or the lungs cannot remove carbon dioxide efficiently enough.
DID YOU KNOW?
Dr. Nasir Husain, the medical director of infectious diseases at Henry Ford Macomb Hospital explained that people who have uncontrolled asthma, people who are not compliant with their medications for COPD (chronic obstructive pulmonary disease), people who have heart failure, congestive heart failure, uncontrolled diabetes are most at risk for complications from COVID-19.
Previous
Next

We will not give up until we triumphantly overcome this crisis together!

Why Use D'OXYVA?

Our organization has been on the forefront in the fight against the novel coronavirus that originated in Wuhan, China (Covid-19) since January of this year due to our organization’s operations in major countries across Asia. We all should understand the need to act now and arrest this crisis head on by spurring economic activity wherever we can and providing effective, affordable and rapid testing and treatments for the masses.

Already, D’OXYVA is in Phase 3 human clinical trials with medical thought-leaders from many of the top ten U.S. university research institutions with our biotech solution for FDA approval for rapidly and affordably treating chronic conditions in just a few weeks, while targeting Covid-19. These include but are not limited to the early bedside and ultra-portable detection and treatment of sepsis and septic shock, inflammation, diabetic wounds, heart disease, hypertension, and various pulmonary and mental diseases, while fighting against Covid-19 with an already FDA-approved simple, non-toxic, and widely used molecule currently available in most hospitals around the world.

Beyond a strong clinical evidence demonstrating massive improvements in blood and tissue oxygenation with blood flow throughout the macro-, and microcirculatory system while significantly improving heart rate variability amongst other inflammatory markers, our existing and new customers who purchase our products on our eCommerce non-prescription website continue to enjoy the amazing health benefits our noninvasive products deliver on four continents.

As you may know, any new coronavirus vaccine that anyone may come up with, requires at least a year of testing and regulatory paperwork, even at the fastest emergency level. The virus now exponentially mutates so vaccines and treatments now being discussed by officials could easily miss the target and fail for most people. Then only systemic (full body) approaches will help since you can’t target one thing inside the body, you need to elicit the resources of the entire body to fight it.

In this case, one of the very few most effective ways to deal with this virus is D’OXYVA’s uniquely powerful systemic benefits. D’OXYVA significantly reduces inflammation, fever, and reinforces the immune system, while improving white blood cell production, oxygen-rich blood circulation, toxic waste removal and a host of inflammatory markers combined with additional powerful beneficial hormonal and neural functions at the same time.

Making this possible are the brave and determined people hard at work at adapting our factories, supply chains and product fulfillment centers to keep humming here at home in the States, Asia, and Europe during these critical times.